BioCentury
ARTICLE | Clinical News

ABO-102: Interim Ph I/II data

December 1, 2016 11:38 AM UTC

Interim data from 3 patients with MPS IIIA in an open-label, U.S. Phase I/II trial showed that a single IV injection of 5x1012 vg/kg ABO-102 was well tolerated with no treatment-related serious advers...